Cidara Therapeutics (Cidara Therapeutics) Total Current Assets : $46.83 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Cidara Therapeutics's total current assets for the quarter that ended in Mar. 2024 was $46.83 Mil.

Cidara Therapeutics Total Current Assets Historical Data

The historical data trend for Cidara Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Total Current Assets Chart

Cidara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

65.81

57.19

71.70

45.09

60.86

Cidara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															79.49	62.24	57.70	60.86	46.83

Cidara Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Cidara Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	35.778	+	16.246	+	6.097	+	2.734
	=	60.86

Cidara Therapeutics's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	29.018	+	7.281	+	7.269	+	3.266
	=	46.83

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Cidara Therapeutics (NAS:CDTX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Cidara Therapeutics's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	29.018	-	70.496	+	0.75 * 7.281	+	0.5 * 7.269
=	-32.38

Cidara Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics (Cidara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

20D:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

Executives

Leslie Tari	officer: Chief Scientific Officer	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison	officer: Chief Medical Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein	director, officer: President & CEO	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward	officer: CHIEF LEGAL OFFICER	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah	officer: CFO & CBO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala	officer: Chief Medical Officer	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson	officer: Dir. of Finance & Controller	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston	director	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder	director	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher	director	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121